- 17 June
-
From May 20 to 22, the first Eurasian International Medical Forum was held in Ekaterinburg. The event was dedicated to the 80th anniversary of Victory in the Great Patriotic War. The Forum brought together over 1,000 participants and 250 experts from Russia, India, China and Belarus. Medsintez Plant took an active part in scientific program of the Forum and demonstrated its latest developments in the field of import-substituting drugs.
- 13 June
-
The X (XXXI) National Diabetes Congress with international participation was held in Moscow from May 27 to 30, 2025. The event was dedicated to the topic «Diabetes mellitus – a non-infectious pandemic of the 21st century. Macro- and microvascular complications. Issues of interdisciplinary interaction». The Congress was dedicated to the 100th anniversary of the Russian Association of Endocrinologists, the Endocrinology Service of the Russian Federation and the Research Center for Endocrinology.
- 10 June
-
In May 2025, pharmaceutical plant Medsintez Plant LLC joined the leading enterprises that were awarded the status of National Champion based on the results of a comprehensive expert selection. Getting the status of National Champion is a significant event for Medsintez Plant, which emphasizes its contribution to the development of the pharmaceutical industry and strengthening the drug safety of Russia.
- 25 April
-
From April 15 to 18, Ekaterinburg hosted the 6th international specialized exhibition and forum Healthcare of the Urals–2025. This year, 130 companies from 34 cities of Russia and the Republic of Belarus took part in the event, presenting over 1000 units of medical equipment and goods. The residents of the Ural Biomedical Cluster were traditionally among the participants, as well as its collective member – the Association of Medical and Pharmaceutical Manufacturers of the Sverdlovsk Region.
- Home
- Cluster members
- As & Co Pharm group LLC
As & Co Pharm group LLC
The enterprise As & Co Pharm group LLC is the Ural pharmaceutical company Asco Pharm. The company is a portfolio project of the Ural Federal University (UrFU) Innovation Development Fund, UrFU Innovation Infrastructure and INNOPORT startup studio. Asco Pharm has been researching and developing medicines and dietary supplements for over 15 years. The flagship project of the company is the development of an innovative original drug for the prevention and treatment of osteoporosis, which is in the process of going through the necessary clinical and bureaucratic procedures. In this regard, in order to accelerate the commercialization of the project, the company, based on this drug, brought to the market an innovative dietary supplement REOCYTAN Calcium- Magnesium-D3. Even during the research period, the project showed excellent results, opening up a completely new approach in the fight against osteoporosis and calcium deficiency. The drug uses a patented formula that has no analogues in the world and an innovative technology for delivering calcium to bone tissue. The project has received great interest from the scientific community in Russia and abroad. With this project, the company won the largest business accelerator in the Urals of the Ural Federal University in 2018 And in 2020, Reocytan won the prestigious medical innovation competition held by TIPA in South Korea. Asco Pharm's portfolio also includes more than 20 developments at various stages: recovery after strokes and severe brain injuries, tissue repair after injuries or severe pathologies (heart failure, AECB, SARS, COVID, etc.) oncoprophylaxis technology, technology for removal of hepatitis B virus complicated by D, technology for preventing an autoimmune response in pneumonia of various etiologies, a line of products that suppress muscular dystrophy, etc.
The company is planning to bring several more brands to the market in the next few years.
Tel.: +7 (922)-115-30-63
E-mail: info@ascopharm.ru
www.ascopharm.ru
www.reocytan-calcium.com
